CASIF (CASI Pharmaceuticals) Cyclically Adjusted FCF per Share: $-2.49 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CASIF CASI Pharmaceuticals Inc CASIF
26 GF Score
Price $0.13
GF Value $1.02
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is CASI Pharmaceuticals Cyclically Adjusted FCF per Share?

CASI Pharmaceuticals CASIF 26 Cyclically Adjusted FCF per Share is $-2.49 as of Jun. 2026. GuruFocus rates CASIF with a GF Score™ of 26/100 and a GF Value™ of $1.02 (Possible Value Trap). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

CASI Pharmaceuticals's adjusted free cash flow per share for the three months ended in Jun. 2026 was $0.000. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-2.49 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of CASI Pharmaceuticals was 38.60% per year. The lowest was -0.60% per year. And the median was 26.50% per year.

As of today (2026-09-17), CASI Pharmaceuticals's current stock price is $0.1288. CASI Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was $-2.49. CASI Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is .


CASI Pharmaceuticals  (OTCPK:CASIF) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


CASI Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


CASI Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for CASI Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals Cyclically Adjusted FCF per Share Chart

CASI Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.11 -2.20 -2.20 -2.22 -2.15

CASI Pharmaceuticals Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.33 -2.37 -2.40 -2.45 -2.49

CASIF vs CMND, VBIO, BIXT: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, CASI Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CASI Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where CASI Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


CASIF
26GF Score
CASI Pharmaceuticals Inc CASIF
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CASI Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CASI Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/116.0564*116.0564
=0.000

Current CPI (Jun. 2026) = 116.0564.

CASI Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200612 -7.269 77.793 -10.844
200706 -10.931 79.357 -15.986
200712 -4.839 82.911 -6.773
200806 -9.704 85.058 -13.241
200812 -2.289 83.956 -3.164
200906 -4.749 83.615 -6.592
200912 -2.758 85.386 -3.749
201006 -2.726 85.886 -3.684
201012 -1.309 89.289 -1.701
201106 -1.774 91.612 -2.247
201112 -0.774 92.885 -0.967
201206 -0.640 93.495 -0.794
201212 -0.339 95.237 -0.413
201306 -0.389 95.984 -0.470
201312 -0.274 97.624 -0.326
201406 -0.414 98.200 -0.489
201412 -0.354 99.000 -0.415
201506 -0.464 99.500 -0.541
201512 -0.398 100.600 -0.459
201606 -0.333 101.400 -0.381
201612 -0.279 102.600 -0.316
201706 -0.360 103.100 -0.405
201712 -0.288 104.500 -0.320
201806 -0.459 104.900 -0.508
201812 -1.692 106.500 -1.844
201906 -0.892 107.700 -0.961
201912 -1.158 111.200 -1.209
202006 -0.643 110.400 -0.676
202012 -0.739 111.500 -0.769
202106 -0.541 111.769 -0.562
202112 -0.920 113.108 -0.944
202206 -0.655 114.558 -0.664
202212 -0.317 115.116 -0.320
202306 0.000 114.558 0.000
202312 0.000 114.781 0.000
202406 0.000 114.781 0.000
202412 0.000 114.893 0.000
202506 0.000 114.907 0.000
202512 0.000 115.832 0.000
202606 0.000 116.056 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-2.49 mean?
CASI Pharmaceuticals (CASIF) has a Cyclically Adjusted FCF per Share of $-2.49 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on CASI Pharmaceuticals and its competitors.
Is CASI Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
CASI Pharmaceuticals' current Cyclically Adjusted FCF per Share is $-2.49. Overall, CASI Pharmaceuticals has a GF Score™ of 26/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does CASI Pharmaceuticals' Cyclically Adjusted FCF per Share compare to CMND and VBIO?
CASI Pharmaceuticals' Cyclically Adjusted FCF per Share of $-2.49 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on CASI Pharmaceuticals and its competitors. CASI Pharmaceuticals's current Cyclically Adjusted FCF per Share is $-2.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CASI Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, CASI Pharmaceuticals (CASIF) is currently considered Possible Value Trap. The stock's GF Value™ is $1.02, compared to a current price of $0.13 — trading 87.4% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $-2.49. CASI Pharmaceuticals' overall GF Score™ is 26/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For CASI Pharmaceuticals (CASIF), the current Cyclically Adjusted FCF per Share is $-2.49 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CASI Pharmaceuticals (CASIF) Overvalued in 2026?

Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued. The current stock price of $0.13 is trading 87.4% below its estimated GF Value™ of $1.02. GuruFocus considers CASI Pharmaceuticals to be Possible Value Trap.

Key valuation signals for CASIF:

  • Cyclically Adjusted FCF per Share: $-2.49
  • GF Value™: $1.02 vs. price of $0.13 (87.4% below fair value)
  • GF Score™: 26/100 with 7 warning signs

No single metric tells the full story. See the CASIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CASI Pharmaceuticals Business Description

Address Jianguo Road, No. 81, Room 1701-1702, China Central Office Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025
CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.
26GF Score

Get the complete analysis for CASIF

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price
$1.02
GF Value